ABT-122双靶点抑制肿瘤坏死因子和白介素-17A:类风湿关节炎或银屑病关节炎的开放标签长期扩展研究
两项开放标签24周扩展研究评估ABT-122(靶向TNF和IL-17A的双特异性单克隆抗体)在类风湿关节炎(RA)或银屑病关节炎(PsA)患者中的安全性和疗效维持。RA扩展研究纳入158例,PsA纳入168例,均皮下注射ABT-122(RA 120 mg;PsA 240 mg)每两周一次,背景甲氨蝶呤。结果示耐受性可接受,ACR应答及其他疾病活动度评分在24周内维持。
要点
- RA扩展研究治疗中出现的不良事件(TEAE)发生率为41%,与双盲研究(36-43%)相似。
- PsA扩展研究57%的患者报告至少1例TEAE(双盲研究为42-53%),大多为轻中度。
- 两项扩展研究中ACR应答及其他疾病活动度评分在24周内维持。
核心结论
- ABT-122在背景甲氨蝶呤治疗的RA或PsA患者中耐受性可接受,疗效维持至36周。
研究设计与样本
- 两项12周随机双盲研究的开放标签24周扩展研究(OLE),所有患者接受ABT-122皮下注射每两周一次(RA 120 mg;PsA 240 mg),背景甲氨蝶呤。
主要发现
- RA扩展研究纳入158例患者,TEAE发生率为41%,与双盲研究(36-43%)相似;PsA扩展研究纳入168例患者,57%报告至少1例TEAE(双盲研究42-53%)。
- 大多数TEAE为轻中度;无中性粒细胞异常超过2级;3级和/或4级实验室异常涉及淋巴细胞、丙氨酸氨基转移酶、天冬氨酸氨基转移酶、胆红素和血红蛋白,严重实验室值数量低(0.6-3.0%),但RA研究中3级淋巴细胞计数降低为11.5%。
- 两项扩展研究中,ACR应答及其他疾病活动度评分在24周内维持。
关键数值与推荐
- RA扩展研究TEAE发生率41%,双盲研究36-43%;PsA扩展研究TEAE发生率57%,双盲研究42-53%。
- 3级和/或4级实验室异常发生率0.6-3.0%,RA研究中3级淋巴细胞计数降低为11.5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the safety and maintenance of efficacy with ABT-122, a bi-specific monoclonal antibody targeting TNF and IL-17A, in patients with RA or PsA in open-label, 24-week extensions [open-label extensions (OLEs)] of 12-week, randomized, double-blind studies. METHODS: All patients received ABT-122 (RA, 120 mg; PsA, 240 mg) subcutaneously every other week on background MTX. Safety assessments included adverse events (AEs) and laboratory parameters. Efficacy was evaluated with ACR responses, 28-joint DAS using high-sensitivity CRP [DAS28 (hsCRP)], and Psoriasis Area and Severity Index (PsA study). RESULTS: The RA OLE study enrolled 158 patients; the PsA OLE study enrolled 168 patients. In the RA OLE study, the incidence of treatment emergent AEs (TEAEs; 41%) appeared similar to the double-blind study (36-43%). In the PsA OLE study, 57% of patients reported ⩾1 TEAE (double-blind study, 42-53%). Most TEAEs were mild or moderate in severity. There were no neutrophil abnormalities greater than grade 2. Grade 3 and/or 4 laboratory abnormalities were reported for lymphocytes, alanine aminotransferase, aspartate aminotransferase, bilirubin and haemoglobin; the number of these severe laboratory values was low (0.6-3.0%), except grade 3 lymphocyte count decreased (11.5%) in the RA study. In both OLE studies, efficacy assessed by ACR responses and other disease activity scores was maintained over the 24 weeks. CONCLUSION: ABT-122 demonstrated acceptable tolerability and maintenance of efficacy for up to 36 weeks in patients with RA or PsA receiving background MTX. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT02433340 and NCT02429895.
引用
- Genovese MC, Weinblatt ME, Mease PJ, et al. Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis. Rheumatology (Oxford). 2018. PMID: 30032191. doi:10.1093/rheumatology/key173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。